Anthony Buisson

7.0k total citations
151 papers, 2.7k citations indexed

About

Anthony Buisson is a scholar working on Genetics, Epidemiology and Surgery. According to data from OpenAlex, Anthony Buisson has authored 151 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 127 papers in Genetics, 101 papers in Epidemiology and 70 papers in Surgery. Recurrent topics in Anthony Buisson's work include Inflammatory Bowel Disease (127 papers), Microscopic Colitis (81 papers) and Autoimmune and Inflammatory Disorders (26 papers). Anthony Buisson is often cited by papers focused on Inflammatory Bowel Disease (127 papers), Microscopic Colitis (81 papers) and Autoimmune and Inflammatory Disorders (26 papers). Anthony Buisson collaborates with scholars based in France, United States and Belgium. Anthony Buisson's co-authors include Gilles Bommelaer, Bruno Pereira, Laurent Peyrin‐Biroulet, Marion Goutte, Jean‐Baptiste Chevaux, Constance Hordonneau, Félix Goutorbe, Patrick B. Allen, Nicolas Barnich and Mathurin Fuméry and has published in prestigious journals such as Gastroenterology, Gut and Scientific Reports.

In The Last Decade

Anthony Buisson

136 papers receiving 2.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anthony Buisson France 32 2.1k 1.7k 1.0k 375 332 151 2.7k
Guillaume Bouguen France 30 1.8k 0.8× 1.3k 0.8× 1.3k 1.3× 288 0.8× 187 0.6× 144 2.8k
J F Colombel United States 29 2.2k 1.0× 1.7k 1.0× 1.4k 1.3× 797 2.1× 389 1.2× 148 3.6k
Gilles Boschetti France 25 1.1k 0.5× 944 0.6× 778 0.8× 538 1.4× 204 0.6× 89 2.0k
Jean-Paul Achkar United States 24 2.0k 0.9× 1.4k 0.9× 1.2k 1.1× 351 0.9× 397 1.2× 31 2.9k
Marcus Harbord United Kingdom 15 2.2k 1.1× 1.6k 1.0× 843 0.8× 637 1.7× 392 1.2× 26 3.0k
Taina Sipponen Finland 28 2.2k 1.0× 1.7k 1.0× 1.1k 1.1× 662 1.8× 218 0.7× 66 2.8k
Ida Vind Denmark 24 1.7k 0.8× 1.4k 0.8× 804 0.8× 335 0.9× 339 1.0× 46 2.3k
Khurram J Khan Canada 12 1.5k 0.7× 1.1k 0.7× 762 0.7× 266 0.7× 303 0.9× 31 2.1k
Stéphane Nancey France 33 2.0k 1.0× 1.7k 1.0× 891 0.9× 893 2.4× 459 1.4× 170 3.3k
Ulla Turunen Finland 23 1.7k 0.8× 1.3k 0.8× 829 0.8× 477 1.3× 224 0.7× 44 2.3k

Countries citing papers authored by Anthony Buisson

Since Specialization
Citations

This map shows the geographic impact of Anthony Buisson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anthony Buisson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anthony Buisson more than expected).

Fields of papers citing papers by Anthony Buisson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anthony Buisson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anthony Buisson. The network helps show where Anthony Buisson may publish in the future.

Co-authorship network of co-authors of Anthony Buisson

This figure shows the co-authorship network connecting the top 25 collaborators of Anthony Buisson. A scholar is included among the top collaborators of Anthony Buisson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anthony Buisson. Anthony Buisson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wang, Zhigang, et al.. (2025). A Risk Stratification Tool for Relapse After Intravenous-To-Subcutaneous Switching of Infliximab in Patients With Inflammatory Bowel Diseases. The American Journal of Gastroenterology. 121(1). 179–186.
2.
Fuméry, Mathurin, et al.. (2025). Switching from intravenous to subcutaneous infliximab is safe and feasible in patients with perianal Crohn’s disease. Therapeutic Advances in Gastroenterology. 18. 1128509447–1128509447.
3.
Barnich, Nicolas, Janelle C. Arthur, Anthony Buisson, et al.. (2025). Adherent-invasive Escherichia coli in Crohn’s disease: the 25th anniversary. Gut. 75(2). 411–424.
4.
5.
6.
7.
Minet‐Quinard, Régine, et al.. (2024). Intestinal Ultrasonography as an Alternative to Fecal Calprotectin to Monitor Patients with Crohn’s Disease: Experience from a Novice Sonographer. Digestive Diseases and Sciences. 69(9). 3402–3412. 2 indexed citations
8.
Buisson, Anthony, Maria Nachury, Clara Yzet, et al.. (2023). Long‐term effectiveness and acceptability of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel disease treated with intensified doses: The REMSWITCH‐LT study. Alimentary Pharmacology & Therapeutics. 59(4). 526–534. 10 indexed citations
9.
Jacomet, Christine, et al.. (2023). Impact of screening programme to prevent anal cancer in high‐risk patients with HIV. HIV Medicine. 25(4). 454–461. 3 indexed citations
10.
Laharie, David, Laurence Picon, D. Gargot, et al.. (2022). How are patients’ preferences for anti-TNF influenced by quality of life? A discrete choice experiment in Crohn’s disease patients. Scandinavian Journal of Gastroenterology. 57(11). 1312–1320. 3 indexed citations
11.
Buisson, Anthony, Harry Sokol, Nassim Hammoudi, et al.. (2022). Role of adherent and invasive Escherichia coli in Crohn’s disease: lessons from the postoperative recurrence model. Gut. 72(1). 39–48. 33 indexed citations
12.
Boschetti, Gilles, Bruno Pereira, Bernard Flourié, et al.. (2021). Comparison of short‐ and long‐term effectiveness between ustekinumab and vedolizumab in patients with Crohn's disease refractory to anti‐tumour necrosis factor therapy. Alimentary Pharmacology & Therapeutics. 53(12). 1289–1299. 33 indexed citations
13.
Buisson, Anthony, Lisa Cannon, Konstantin Umanskiy, et al.. (2021). Factors associated with anti-tumor necrosis factor effectiveness to prevent postoperative recurrence in Crohn’s disease. Intestinal Research. 20(3). 303–312. 10 indexed citations
14.
Agus, Allison, Damien Richard, Tiphanie Faïs, et al.. (2021). Propionate catabolism by CD-associated adherent-invasive E. coli counteracts its anti-inflammatory effect. Gut Microbes. 13(1). 1–18. 25 indexed citations
15.
Buisson, Anthony, Stéphane Nancey, David T. Rubin, et al.. (2021). Ustekinumab is more effective than azathioprine to prevent endoscopic postoperative recurrence in Crohn's disease. United European Gastroenterology Journal. 9(5). 552–560. 34 indexed citations
16.
Bourrier, Anne, Maria Nachury, Stéphane Nancey, et al.. (2020). Vedolizumab for perianal Crohn’s disease: a multicentre cohort study in 151 patients. Alimentary Pharmacology & Therapeutics. 51(7). 719–727. 46 indexed citations
17.
Laharie, David, Stéphane Nancey, Xavier Hébuterne, et al.. (2020). Variation of faecal calprotectin level within the first three months after bowel resection is predictive of endoscopic postoperative recurrence in Crohn's disease. Digestive and Liver Disease. 52(7). 740–744. 10 indexed citations
18.
Auzolle, Claire, Stéphane Nancey, My‐Linh Tran‐Minh, et al.. (2018). Male gender, active smoking and previous intestinal resection are risk factors for post‐operative endoscopic recurrence in Crohn's disease: results from a prospective cohort study. Alimentary Pharmacology & Therapeutics. 48(9). 924–932. 63 indexed citations
19.
Buisson, Anthony, Constance Hordonneau, Félix Goutorbe, et al.. (2018). Bowel wall healing assessed using magnetic resonance imaging predicts sustained clinical remission and decreased risk of surgery in Crohn’s disease. Journal of Gastroenterology. 54(4). 312–320. 37 indexed citations
20.
Martineau, Chloé, Bernard Flourié, Pauline Wils, et al.. (2017). Efficacy and safety of golimumab in Crohn's disease: a French national retrospective study. Alimentary Pharmacology & Therapeutics. 46(11-12). 1077–1084. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Guillaume Bouguen Breakdown of academic impact, for papers by J F Colombel Breakdown of academic impact, for papers by Gilles Boschetti Breakdown of academic impact, for papers by Jean-Paul Achkar Breakdown of academic impact, for papers by Marcus Harbord Breakdown of academic impact, for papers by Taina Sipponen Breakdown of academic impact, for papers by Ida Vind Breakdown of academic impact, for papers by Khurram J Khan Breakdown of academic impact, for papers by Stéphane Nancey Breakdown of academic impact, for papers by Ulla Turunen
Rankless by CCL
2026